Cargando…
Long-term safety evaluation of Daxocox(®) tablets (enflicoxib) in dogs after weekly oral administrations for seven months
BACKGROUND: Daxocox® [Ecuphar/Animalcare Group] contains the selective COX-2 inhibitor enflicoxib, approved in the EU for the treatment of pain and inflammation associated with osteoarthritis in dogs. The safety of Daxocox(®) was evaluated in a target animal safety study: Groups of 4 dogs per sex ea...
Autores principales: | Homedes, Josep, Salichs, Marta, Guzman, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173827/ https://www.ncbi.nlm.nih.gov/pubmed/34082759 http://dx.doi.org/10.1186/s12917-021-02910-0 |
Ejemplares similares
-
Pharmacokinetics of enflicoxib in dogs: Effects of prandial state and repeated administration
por: Homedes, Josep, et al.
Publicado: (2021) -
Evaluation of the Genotoxic Potential of the Selective COX-2
Inhibitor Enflicoxib in a Battery of
in vitro
and
in vivo
Genotoxicity Assays
por: Guzmán, Antonio, et al.
Publicado: (2022) -
Comparative In vitro Metabolism of Enflicoxib in Dogs, Rats, and Humans: Main Metabolites and Proposed Metabolic Pathways
por: Solà, Josep, et al.
Publicado: (2021) -
Enflicoxib for canine osteoarthritis: A randomized, blind, multicentre, non-inferiority clinical trial compared to mavacoxib
por: Salichs, Marta, et al.
Publicado: (2022) -
Pharmacology of enflicoxib, a new coxib drug: Efficacy and dose determination by clinical and pharmacokinetic‐guided approach for the treatment of osteoarthritis in dogs based on an acute arthritis induction model
por: Cendrós, Josep‐Maria, et al.
Publicado: (2021)